ArticleCellular & molecular immunology2017
Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells.
Article in Cellular & molecular immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.EBioMedicine · 2026Article
- Langerhans cells: Central players in the pathophysiology of atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- The roles of tissue resident macrophages in health and cancer.Experimental hematology & oncology · 2024Review
- Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.Frontiers in immunology · 2023Review
- Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine.Frontiers in immunology · 2023Review
- Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.Vaccines · 2022Review
- The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.Frontiers in immunology · 2022Review
- Medicinal chemistry of the myeloid C-type lectin receptors Mincle, Langerin, and DC-SIGN.RSC medicinal chemistry · 2021Review
- Herpes Simplex Virus type 1 infects Langerhans cells and the novel epidermal dendritic cell, Epi-cDC2s, via different entry pathways.PLoS pathogens · 2021Article
- Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin.Frontiers in immunology · 2021Article
- Immune Phenotypes of Nasopharyngeal Cancer.Cancers · 2020Article
- Rational Design of a DNA-Scaffolded High-Affinity Binder for Langerin.Angewandte Chemie (International ed. in English) · 2020Article
- The role of Langerhans cells in epidermal homeostasis and pathogenesis of psoriasis.Journal of cellular and molecular medicine · 2020Review
- Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review.Pharmaceutics · 2020Review
- Targeting of the C-Type Lectin Receptor Langerin Using Bifunctional Mannosylated Antigens.Frontiers in cell and developmental biology · 2020Article
- The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8Pharmaceutics · 2019Review
- A Liposomal Platform for Delivery of a Protein Antigen to Langerin-Expressing Cells.Biochemistry · 2019Article
- A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell Targeting.ACS central science · 2019Article
- Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.Theranostics · 2019Article
- Differentiation of Langerhans Cells from Monocytes and Their Specific Function in Inducing IL-22-Specific Th Cells.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.